How to buy Takeda Pharmaceutical Company stock | $16.78

Takeda Pharmaceutical Company Limited is a drug manufacturers-specialty & generic business based in the US. Takeda Pharmaceutical Company shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical Company employs 47,099 staff and has a trailing 12-month revenue of around 0.00.

Takeda Pharmaceutical Company stock price (NYSE: TAK)

Use our graph to track the performance of TAK stocks over time.

Takeda Pharmaceutical Company shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$16.78
52-week range	$15.30 - $19.97
50-day moving average	$16.88
200-day moving average	$17.39
Wall St. target price	$21.78
PE ratio	15.8862
Dividend yield	$180 (4.06%)
Earnings per share (TTM)	$1.08

Buy Takeda Pharmaceutical Company shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Takeda Pharmaceutical Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Takeda Pharmaceutical Company Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Takeda Pharmaceutical Company price performance over time

Historical closes compared with the close of $16.78 from 2021-06-08

1 week (2021-07-22)	N/A
1 month (2021-07-02)	-0.53%
3 months (2021-04-30)	0.48%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Is Takeda Pharmaceutical Company under- or over-valued?

Valuing Takeda Pharmaceutical Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Takeda Pharmaceutical Company's P/E ratio

Takeda Pharmaceutical Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Takeda Pharmaceutical Company shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Takeda Pharmaceutical Company's PEG ratio

Takeda Pharmaceutical Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3994. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Takeda Pharmaceutical Company's EBITDA

Takeda Pharmaceutical Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $899.4 billion.

The EBITDA is a measure of a Takeda Pharmaceutical Company's overall financial performance and is widely used to measure a its profitability.

Takeda Pharmaceutical Company financials

Revenue TTM	$3,197.8 billion
Operating margin TTM	12.7%
Gross profit TTM	$2,203.6 billion
Return on assets TTM	1.97%
Return on equity TTM	7.6%
Profit margin	11.76%
Book value	$1,654.46
Market capitalisation	$54.1 billion

TTM: trailing 12 months

Shorting Takeda Pharmaceutical Company shares

There are currently 6.0 million Takeda Pharmaceutical Company shares held short by investors – that's known as Takeda Pharmaceutical Company's "short interest". This figure is 6.4% up from 5.6 million last month.

There are a few different ways that this level of interest in shorting Takeda Pharmaceutical Company shares can be evaluated.

Takeda Pharmaceutical Company's "short interest ratio" (SIR)

Takeda Pharmaceutical Company's "short interest ratio" (SIR) is the quantity of Takeda Pharmaceutical Company shares currently shorted divided by the average quantity of Takeda Pharmaceutical Company shares traded daily (recently around 2.0 million). Takeda Pharmaceutical Company's SIR currently stands at 2.97. In other words for every 100,000 Takeda Pharmaceutical Company shares traded daily on the market, roughly 2970 shares are currently held short.

However Takeda Pharmaceutical Company's short interest can also be evaluated against the total number of Takeda Pharmaceutical Company shares, or, against the total number of tradable Takeda Pharmaceutical Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Takeda Pharmaceutical Company's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Takeda Pharmaceutical Company shares in existence, roughly 0 shares are currently held short) or 0.0019% of the tradable shares (for every 100,000 tradable Takeda Pharmaceutical Company shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Takeda Pharmaceutical Company.

Find out more about how you can short Takeda Pharmaceutical Company stock.

Takeda Pharmaceutical Company share dividends

Dividend payout ratio: 74.43% of net profits

Recently Takeda Pharmaceutical Company has paid out, on average, around 74.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.97% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical Company shareholders could enjoy a 4.97% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical Company's case, that would currently equate to about $180 per share.

Takeda Pharmaceutical Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Takeda Pharmaceutical Company's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 29 March 2021 (the "ex-dividend date").

Takeda Pharmaceutical Company share price volatility

Over the last 12 months, Takeda Pharmaceutical Company's shares have ranged in value from as little as $15.3 up to $19.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical Company's is 1.1171. This would suggest that Takeda Pharmaceutical Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Takeda Pharmaceutical Company overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc. ; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.

Frequently asked questions

What percentage of Takeda Pharmaceutical Company is owned by insiders or institutions?
Currently 0.01% of Takeda Pharmaceutical Company shares are held by insiders and 3.497% by institutions. How many people work for Takeda Pharmaceutical Company?
Latest data suggests 47,099 work at Takeda Pharmaceutical Company. When does the fiscal year end for Takeda Pharmaceutical Company?
Takeda Pharmaceutical Company's fiscal year ends in March. Where is Takeda Pharmaceutical Company based?
Takeda Pharmaceutical Company's address is: 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668 What is Takeda Pharmaceutical Company's ISIN number?
Takeda Pharmaceutical Company's international securities identification number is: US8740602052 What is Takeda Pharmaceutical Company's CUSIP number?
Takeda Pharmaceutical Company's Committee on Uniform Securities Identification Procedures number is: 874060106